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Edirorial Comment
Bisphosphonates are widely employed to decrease bone
loss in disorders characterized by increased osteoclast-
mediated bone resorption, such as senile osteoporosis.1 Al-
though generally well-tolerated, side effects such as an
acute inflammatory phase reaction, osteonecrosis of the
jaw, gastrointestinal disorders, or hypocalcemia have been
described.1 Also, contradictory reports of an association be-
tween atrial fibrillation (AF) and the use of bisphosphonates
has led to confusing statements and sent mixed messages to
practitioners and patients.2 Details on these conflicting ob-
servations are summarized in previously published review
articles.1-3 Interestingly, several hypotheses linking bisphos-
phonates to the onset of AF have been formulated: an acute
increase in proinflammatory cytokines, disturbances in cal-
cium homeostasis, or extracellular matrix remodeling.2 To
date, however, none of these premises have been tested, the
mechanisms by which bisphosphonates may impact cardiac
electrophysiology are unknown, and as of late 2008, the Food
and Drug Administration failed to identify a clear association
and concluded that no change in prescribing practices was
warranted.1,2
In this issue of the Journal of Cardiovascular Electrophys-
iology, Bonilla et al. present a multifaceted investigation de-
scribing plausible mechanisms for bisphosphonate-induced
cardiac arrhythmias.4 Their results have substantial mecha-
nistic depth and, albeit provocative, put at question the pre-
vious status quo on an association between bisphosphonates
and cardiac arrhythmias.
The authors started their work with a clinical ob-
servation compatible, although inconclusively, with a
bisphosphonate-induced arrhythmia. A 55-year-old woman,
having had a single dose of ibandronate—a commonly used
bisphosphonate—experienced syncope and subsequently
presented with QT/QTc interval prolongation, which nor-
malized following ibandronate discontinuation. Based upon
this suspicious observation, the authors conducted a compre-
hensive basic and translational investigation that included a
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3-month treatment of canines with ibandronate, subsequent
cell electrophysiology-patch-clamp and intracellular calcium
measurements, and numerical simulations.
The authors demonstrate clearly that ibandronate exerts a
massive effect on myocyte electrophysiology. First, the ac-
tion potential duration (APD) is about 30–40% prolonged
with early after depolarizations arising significantly more
after ibandronate perfusion. Also, the authors noticeably
show that the repolarizing current Ito, both slope conduc-
tance and maximal density, is reduced by ibandronate and
that ibandronate-related APD changes are heavily dependent
on the sarcoplasmic reticulum (SR) calcium-controlling re-
ceptor, the ryanodine receptor (RyR). When the RyR was
blocked after ryanodine perfusion, or that the calcium was
chelated with BAPTA, none of the APD changes described
above were seen. Besides, ibandronate treatment caused a
significant increase in calcium load and a decrease in cal-
cium spark amplitude, while spark intensity was rebound-
ing during washout. The latter observation could be an
important insight as the proarrhythmic action may follow bis-
phosphonates withdrawal rather than associate with its use.
Altogether, two seemingly independent mechanisms were
probably at play: a decrease in repolarization reserve with
a decreased Ito current, and RyR blocking action with in-
creased SR load. In silico, an additional potentially critical
finding was that the forward RyR inactivation rate may un-
derlie bisphosphonate-related Ito current decrease and APD
prolongation. Although the means by which the former is
mechanistically related to the latter remain unclear, these
original mechanisms are likely additive as both were needed
to mimic experimental APD prolongation.
Hence, this well-conducted study yields solid evidence
that ibandronate—and presumably other bisphosphonates—
adversely modulate cardiac myocyte electrophysiology.
Nonetheless, it is uncertain whether these findings trans-
late to the organ or the in vivo realities. As pointed out by
the authors, compensatory mechanisms such as intercellular
communication, a modulation of the autonomic nervous in-
put, or an increased inflammation could sum up to a much
lesser effect that the one seen in isolated cells. Still, the
work presented by Bonilla et al. stands as a compelling
mechanistic dataset that helps in appreciating bisphospho-
nates’ impact on cardiac electrophysiology. This effort war-
rants further investigation to clarify cellular mechanisms,
and to assess whether atrial myocytes are similarly sensi-
tive to bisphosphonates. Also, this work is a call for clinical
studies focused on a detailed analysis of the time period
following bisphosphonates withdrawal. Altogether, Bonilla
et al.’s observations are a strong scholarly incentive for a
comprehensive research program aiming at elucidating the
effects of bisphosphonates on the heart.
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